Vaccines for COVID-19
JS Tregoning, ES Brown… - Clinical & …, 2020 - academic.oup.com
Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019,
there has been an explosion of vaccine development. By 24 September 2020, a staggering …
there has been an explosion of vaccine development. By 24 September 2020, a staggering …
From SARS to MERS, thrusting coronaviruses into the spotlight
Z Song, Y Xu, L Bao, L Zhang, P Yu, Y Qu, H Zhu… - viruses, 2019 - mdpi.com
Coronaviruses (CoVs) have formerly been regarded as relatively harmless respiratory
pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused …
pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused …
Circulating spike protein detected in post–COVID-19 mRNA vaccine myocarditis
Background: Cases of adolescents and young adults developing myocarditis after
vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–targeted …
vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–targeted …
SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
COVID-19 vaccine: where are we now and where should we go?
S Soleimanpour, A Yaghoubi - Expert review of vaccines, 2021 - Taylor & Francis
Introduction The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has
currently caused the pandemic with a high progressive speed and has been considered as …
currently caused the pandemic with a high progressive speed and has been considered as …
[HTML][HTML] Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses
JT Ladner, SN Henson, AS Boyle… - Cell Reports …, 2021 - cell.com
The SARS-CoV-2 proteome shares regions of conservation with endemic human
coronaviruses (CoVs), but it remains unknown to what extent these may be cross …
coronaviruses (CoVs), but it remains unknown to what extent these may be cross …
Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies
DO Ricke - Frontiers in immunology, 2021 - frontiersin.org
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-
like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease …
like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease …
[HTML][HTML] Validation of a commercially available SARS-CoV-2 serological immunoassay
B Meyer, G Torriani, S Yerly, L Mazza, A Calame… - Clinical microbiology …, 2020 - Elsevier
Objectives To validate the diagnostic accuracy of a Euroimmun SARS-CoV-2 IgG and IgA
immunoassay for COVID-19. Methods In this unmatched (1: 2) case-control validation study …
immunoassay for COVID-19. Methods In this unmatched (1: 2) case-control validation study …
The spike protein of SARS-CoV—a target for vaccine and therapeutic development
L Du, Y He, Y Zhou, S Liu, BJ Zheng… - Nature Reviews …, 2009 - nature.com
Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused
by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is …
by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is …
Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions
E Gavor, YK Choong, SY Er, H Sivaraman… - Trends in …, 2020 - cell.com
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …